共 50 条
- [41] Energy Trial in Warm Autoimmune Hemolytic Anemia (wAIHA): Design of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn BlockerBLOOD, 2022, 140 : 2445 - 2446Murakhovskaya, IrinaFattizzo, BrunoEbrahim, TarekSweet, KristenShu, Cathye
- [42] A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS- CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study)LANCET REGIONAL HEALTH-AMERICAS, 2023, 21Hernandez-Bernal, FranciscoRicardo-Cobas, Maria C.Martin-Bauta, YenimaRodriguez-Martinez, ErnestoUrrutia-Perez, KlaudiaUrrutia-Perez, KarenQuintana-Guerra, JoelNavarro-Rodriguez, ZadisPinera-Martinez, MarjorisRodriguez-Reinoso, Jose L.Chavez-Chong, Cristina O.Baladron-Castrillo, IdaniaMelo-Suarez, GrettelBatista-Izquierdo, AlejandroPupo-Mico, AlexisMora-Betancourt, RicardoBizet-Almeida, JacquelineMartinez-Rodriguez, Maria C.Lobaina-Lambert, LeonardoVelazquez-Perez, Vivian M.Soler-Diaz, JalimyLaurencio-Vallina, SandraMerino-Hechavarria, TamaraCarmenaty-Campos, NorbertoRodriguez-Montero, EnriLimonta-Fernandez, MiladysAlonso-Valdes, MarelHernandez-Rodriguez, ReinierPimentel-Vazquez, EulogioCatasus-Alvarez, Karem M.Cabrera-Nunez, Maria, VAyala-Avila, MartaMuzio-Gonzalez, Verena L.ABDALA Res Grp
- [43] A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SCGASTROENTEROLOGY, 2012, 142 (05) : S161 - S161Sandborn, W. J.Feagan, B. G.Marano, C. W.Strauss, R.Johanns, J.Zhang, H.Colombel, J.Reinisch, W.Gibson, P.Collins, J.Jarnerot, G. A.Rutgeerts, P. J.
- [44] Effect of Age on the Efficacy and Safety of Cabozantinib compared to Placebo in Patients with radioiodine-refractory (RAIR) differentiated Thyroid Cancer (DTC) who progressed after VEGFR-directed Therapy: Subgroup Analysis of the Phase 3 COSMIC 311 StudyONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 155 - 155Duque-Afonso, J.Robinson, B.Sherman, S., IKrajewska, J.Lin, C-CVaisman, F.Hoff, A. O.Hitre, E.Bowles, D. W.Hernando, J.Banerjee, K.Levytskyy, R. M.Oliver, J. W.Keam, B.Capdevila, J.Brose, M.
- [45] Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver diseaseBMJ OPEN, 2020, 10 (09): : e037961Kessoku, TakaomiKobayashi, TakashiOzaki, AnnaIwaki, MichihiroHonda, YasushiOgawa, YujiImajo, KentoSaigusa, YusukeYamamoto, KojiYamanaka, TakeharuUsuda, HarukiWada, KoichiroYoneda, MasatoSaito, SatoruNakajima, Atsushi
- [46] A double-blind, 4-block randomized, placebo-controlled, adaptive phase 2/3 trial to confirm efficacy and safety of BLS-ILB-E710c in patients with cervical intraepithelial neoplasia 2/3 with extension studyGYNECOLOGIC ONCOLOGY, 2023, 176 : S187 - S188Ouh, Yung-TaekSong, Seung HunKim, Young TaeCho, Chi-HeumKim, Tae JinMin, Seong SuLee, Do YoungPark, Young-ChulLee, Jae Kwan
- [47] Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocolBMJ OPEN, 2022, 12 (10):Ludvigsson, JohnnyEriksson, LinneaNowak, ChristophTeixeira, Pedro F.Widman, MartinaLindqvist, AntonCasas, RosauraLind, MarcusHannelius, Ulf
- [48] Efficacy and Safety of Dapagliflozin Add-on Therapy to Evogliptin plus Metformin Combinations in Inadequately Controlled Patients with Type 2 Diabetes-A 24-Week, Randomized, Double-blind, Placebo-Controlled, Parallel-Design, Phase 3 TrialDIABETES, 2023, 72Jeong, In-KyungChoi, Kyung MookHan, Kyung AhKim, Kyoung-AhKim, In JooHan, Seung JinLee, Won-YoungYoo, Soon Jib
- [49] Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionAMERICAN HEART JOURNAL, 2021, 231 : 121 - 127Gibson, C. MichaelKastelein, John J. P.Phillips, Adam T.Aylward, Philip E.Yee, Megan K.Tendera, MichalNicholls, Stephen J.Pocock, StuartGoodman, Shaun G.Alexander, John H.Lincoff, MichaelBode, ChristophDuffy, DanielleHeise, MarkBerman, GailMears, Sojaita JennyTricoci, PierluigiDeckelbaum, Lawrence I.Steg, P. GabrielRidker, PaulMehran, Roxana
- [50] A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E-CELERATE) (NCT05181540) - Trials in ProgressBLOOD, 2022, 140 : 10573 - 10574Scordo, MichaelShouse, GeoffreyMountjoy, LukeGauthier, JordanDholaria, BhagirathbhaiRowley, Scott D.Pantin, Jeremy M.Defilipp, ZachariahMead, MonicaFinnegan, Paul